Resultados de búsqueda - Richard D. DiMarchi

Limitar resultados
  1. 1
    Fibroblast growth factor 21 night watch: advances and uncertainties in the field

    Fibroblast growth factor 21 night watch: advances and uncertainties in the field por Alexei Kharitonenkov, Richard D. DiMarchi

    Publicado 2016
    Enlace del recurso Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  2. 2
    Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety

    Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety por Rongjun He, Brian Finan, John P. Mayer, Richard D. DiMarchi

    Publicado 2019
    Enlace del recurso Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  3. 3
    Anti-obesity drug discovery: advances and challenges

    Anti-obesity drug discovery: advances and challenges por Timo D. Müller, Matthias Blüher, Matthias H. Tschöp, Richard D. DiMarchi

    Publicado 2021
    Enlace del recurso Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  4. 4
    Anti-Obesity Therapy: from Rainbow Pills to Polyagonists

    Anti-Obesity Therapy: from Rainbow Pills to Polyagonists por Timo D. Müller, Christoffer Clemmensen, Brian Finan, Richard D. DiMarchi, M. Tschöp

    Publicado 2018
    Enlace del recurso Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  5. 5
    Optimization of the Native Glucagon Sequence for Medicinal Purposes

    Optimization of the Native Glucagon Sequence for Medicinal Purposes por Joseph R. Chabenne, Maria A. DiMarchi, Vasily M. Gelfanov, Richard D. DiMarchi

    Publicado 2010
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  6. 6
    Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology

    Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology por Sara J. Brandt, Timo D. Müller, Richard D. DiMarchi, M. Tschöp, Kerstin Stemmer

    Publicado 2018
    Enlace del recurso Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  7. 7
    Insulin analogues and their potential in the management of diabetes mellitus

    Insulin analogues and their potential in the management of diabetes mellitus por Geremia B. Bolli, Richard D. Di Marchi, G. D. Park, Stig Pramming, Veikko A Koivisto

    Publicado 1999
    Enlace del recurso Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  8. 8
    Effect of targeted estrogen delivery using glucagon-like peptide-1 on insulin secretion, insulin sensitivity and glucose homeostasis

    Effect of targeted estrogen delivery using glucagon-like peptide-1 on insulin secretion, insulin sensitivity and glucose homeostasis por Joseph P. Tiano, Chandra R. Tate, Bin Yang, Richard D. DiMarchi, Franck Mauvais‐Jarvis

    Publicado 2015
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  9. 9
    Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes

    Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes por Megan E. Capozzi, Richard D. DiMarchi, Matthias H. Tschöp, Brian Finan, Jonathan E. Campbell

    Publicado 2018
    Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  10. 10
    The metabolic actions of glucagon revisited

    The metabolic actions of glucagon revisited por Kirk M. Habegger, Kristy M. Heppner, Nori Geary, Timothy J. Bartness, Richard D. DiMarchi, Matthias H. Tschöp

    Publicado 2010
    Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  11. 11
    Gαs regulates Glucagon-Like Peptide 1 Receptor-mediated cyclic AMP generation at Rab5 endosomal compartment

    Gαs regulates Glucagon-Like Peptide 1 Receptor-mediated cyclic AMP generation at Rab5 endosomal compartment por Shravan Babu Girada, Ramya S. Kuna, Shilpak Bele, Zhimeng Zhu, N.R. Chakravarthi, Richard D. DiMarchi, Prasenjit Mitra

    Publicado 2017
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  12. 12
    Contribution of brown adipose tissue activity to the control of energy balance by GLP-1 receptor signalling in mice

    Contribution of brown adipose tissue activity to the control of energy balance by GLP-1 receptor signalling in mice por Kristy M. Heppner, Sarah Marks, Jenna Holland, Nickki Ottaway, David L. Smiley, Richard D. DiMarchi, Diego Pérez–Tilve

    Publicado 2015
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  13. 13
    Peptide lipidation stabilizes structure to enhance biological function

    Peptide lipidation stabilizes structure to enhance biological function por Brian Ward, Nickki Ottaway, Diego Pérez–Tilve, Dejian Ma, Vasily M. Gelfanov, Matthias H. Tschöp, Richard D. DiMarchi

    Publicado 2013
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  14. 14
    GLP-1/glucagon receptor co-agonism for treatment of obesity

    GLP-1/glucagon receptor co-agonism for treatment of obesity por Miguel A. Sánchez-Garrido, Sara J. Brandt, Christoffer Clemmensen, Timo D. Müller, Richard D. DiMarchi, Matthias H. Tschöp

    Publicado 2017
    Enlace del recurso Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  15. 15
    Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism

    Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism por Piotr Mróz, Brian Finan, Vasily M. Gelfanov, Bin Yang, Matthias H. Tschöp, Richard D. DiMarchi, Diego Pérez–Tilve

    Publicado 2018
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  16. 16
    GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications

    GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications por Jonathan E. Campbell, Timo D. Müller, Brian Finan, Richard D. DiMarchi, Matthias H. Tschöp, David A. D’Alessio

    Publicado 2023
    Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  17. 17
    Unimolecular Polypharmacy for Treatment of Diabetes and Obesity

    Unimolecular Polypharmacy for Treatment of Diabetes and Obesity por Matthias H. Tschöp, Brian Finan, Christoffer Clemmensen, Vasily M. Gelfanov, Diego Pérez–Tilve, Timo D. Müller, Richard D. DiMarchi

    Publicado 2016
    Enlace del recurso Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  18. 18
    Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes

    Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes por Qiming Tan, Seun Akindehin, Camila E. Orsso, Richelle C. Waldner, Richard D. DiMarchi, Timo D. Müller, Andrea M. Haqq

    Publicado 2022
    Enlace del recurso Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  19. 19
    A glucagon analog chemically stabilized for immediate treatment of life-threatening hypoglycemia

    A glucagon analog chemically stabilized for immediate treatment of life-threatening hypoglycemia por Joseph R. Chabenne, Maria DiMarchi Chabenne, Yan Zhao, Jay J. Levy, David L. Smiley, Vasily M. Gelfanov, Richard D. DiMarchi

    Publicado 2014
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  20. 20
    Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice

    Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice por Sigrid Jall, Stephan Sachs, Christoffer Clemmensen, Brian Finan, Frauke Neff, Richard D. DiMarchi, Matthias H. Tschöp, Timo D. Müller, Susanna M. Hofmann

    Publicado 2017
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:

Herramientas de búsqueda: